Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 18.32K | 595.08K | 879.78K | 573.12K | 907.58K |
Gross Profit | -301.45K | 281.80K | 612.64K | 399.92K | 640.45K |
EBITDA | -2.97M | -3.14M | -2.92M | -2.39M | -2.05M |
Net Income | -2.41M | -3.10M | -2.80M | -2.36M | -1.87M |
Balance Sheet | |||||
Total Assets | 3.16M | 3.84M | 7.30M | 5.00M | 6.57M |
Cash, Cash Equivalents and Short-Term Investments | 2.21M | 2.99M | 6.34M | 3.93M | 5.52M |
Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 11.66K |
Total Liabilities | 368.45K | 613.88K | 1.03M | 754.57K | 567.29K |
Stockholders Equity | 2.79M | 3.22M | 6.27M | 4.25M | 6.00M |
Cash Flow | |||||
Free Cash Flow | -2.76M | -3.28M | 36.67K | -1.83M | -1.64M |
Operating Cash Flow | -2.75M | -3.28M | 43.52K | -1.83M | -1.64M |
Investing Cash Flow | -5.70K | 0.00 | -6.84K | -3.03K | 0.00 |
Financing Cash Flow | 1.98M | -75.00K | 4.41M | 239.88K | 2.67M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
57 Neutral | AU$6.24M | 55.33 | 2.14% | ― | ― | ― | |
52 Neutral | $7.65B | 0.16 | -63.14% | 2.08% | 16.38% | 0.82% | |
46 Neutral | AU$2.23M | ― | -392.18% | ― | ― | 34.26% | |
42 Neutral | AU$6.41M | ― | ― | ― | ― | ||
― | $3.20M | ― | -263.02% | ― | ― | ― | |
― | AU$4.84M | ― | -983.90% | ― | ― | ― | |
40 Underperform | AU$2.17M | ― | -45.96% | ― | ― | -26.67% |
Bio-Gene Technology Ltd announced a correction to a previous statement regarding the proposed issue of securities. This update, which addresses a typographic error, pertains to the company’s plans to offer securities under a securities purchase plan. The correction ensures clarity in the company’s communication with stakeholders and aligns with ASX listing rules, potentially impacting investor confidence and market positioning.
Bio-Gene Technology Ltd has announced a proposed issue of securities, including unlisted options and ordinary fully paid shares, as part of a securities purchase plan and placement. This move is expected to enhance the company’s financial position, potentially enabling further development of its insecticide products and strengthening its market presence.
Bio-Gene Technology Ltd. presented an investor update highlighting its progress in developing nature-derived insecticides. This initiative is expected to enhance the company’s market positioning by offering sustainable solutions to pest control, potentially impacting stakeholders positively by addressing global insecticide needs.
Bio-Gene Technology Ltd announced a successful capital raise of $2.1 million through a placement with sophisticated investors and plans to offer a Share Purchase Plan to eligible shareholders. The funds will be used to conduct regulatory-enabling safety studies for Flavocide®, a key step towards its approval in Australia, and to support the scale-up of Qcide, product development, and strategic projects. This financial boost is expected to significantly advance Bio-Gene’s operational capabilities and strengthen its position in the pest control industry.
Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference 2025, where CEO Tim Grogan will present the company’s advancements in bio-insecticides. This presentation highlights Bio-Gene’s commitment to addressing insecticide resistance and toxicity issues, potentially enhancing its market position and offering stakeholders innovative solutions for pest management.
Bio-Gene Technology Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO Tim Grogan will present on the company’s innovative insecticide solutions. This presentation highlights Bio-Gene’s commitment to addressing pest control challenges and could enhance its visibility and positioning in the bio-insecticide industry, potentially impacting stakeholders by showcasing its environmentally friendly and effective products.
Bio-Gene Technology Limited reported several key achievements for the six months ending December 2024, including a collaboration with Envu to develop Flavocide® for mosquito management, successful pilot-scale production of Flavocide, and the initiation of safety studies in Europe and India. The company also completed its thirteenth Qcide® harvest, improved seed and seedling production, and expanded formulation development programs. Additionally, Bio-Gene strengthened its intellectual property portfolio with six new patents and five new applications, positioning itself strongly in the bio-insecticide market.